In a phase 3 study of virologically suppressed adults with HIV, switching to once-daily doravirine/islatravir (DOR/ISL 100/0.25 mg) maintained high rates of viral suppression through 96 weeks, with no emergent resistance and a favorable safety profile.
Traws Pharma announced positive phase 2 results showing its investigational COVID-19 antiviral ratutrelvir as a possible alternative to Paxlovid, including for ineligible patients, while advancing tivoxavir marboxil as a once-monthly oral prophylactic for seasonal influenza.
This week, read about the changes to the pediatric vaccine schedule, RSV protection, the FDA reversing course on Moderna's influenza vaccine, and more.
The latest CDC numbers show a 7.9% increase of measles cases from week-to-week. While the number of new measles cases are down from the previous week, there are more states and outbreaks circulating throughout the US.
In this month's column, we look at the recommendation changes made by the CDC to the pediatric vaccine schedule, as well as the American Academy of Pediatrics' response with its own vaccine schedule.
New phase 3 data show that Merck’s clesrovimab (Enflonsia) maintained a favorable safety profile and supportive pharmacokinetics in high-risk children under 2 years of age during a second RSV season. The company plans to file for expanded regulatory approval.
The federal agency is bringing over NIH Director Jayanta "Jay" Bhattacharya, MD, PhD, to fill the position.
Invivyd has aligned with the FDA on the design of a phase 3 trial evaluating the safety and immunology of the company's monoclonal antibody, VYD2311, vs mRNA COVID vaccines and in co-administration.
New real-world evidence presented by GSK shows its RSV vaccine, Arexvy, was associated with substantial reductions in RSV-related hospitalizations and serious cardiovascular and respiratory complications among older adults.
After initially refusing to review Moderna’s investigational mRNA-based seasonal influenza vaccine, the company communicated with the FDA on a revised proposal to seek approval and the federal agency will now review the product. The vaccine's PDUFA decision date is August 5, 2026.
Eric Hall, PhD, MPH, led a modeling study around delaying the universal birth dose for the hepatitis B vaccine, and he offered some insights into potential health care costs when moving away from this dosing.
A newly proposed federal insurance rule for 2027 omits long-promised protections on co-pay assistance, allowing insurers and pharmacy benefit managers to continue diverting billions of dollars intended to help patients afford prescription drugs.
Findings from a real-world population study from Spain show that universal infant immunization with Beyfortus significantly reduced RSV-related hospitalizations not only in the first RSV season but also into the second year of life.
A 6-year study in Liberia shows that Lassa fever is frequently missed in febrile patients, leading to preventable deaths and underscoring the urgent need for earlier diagnosis and improved testing.
This week, listen in on commentary around the potential removal of the COVID-19 vaccine from the US market, read about FDA's refusal to review Moderna's influenza vaccine, CDC's investigation on invasive E coli, and more.
The latest CDC numbers show a nearly 25% increase of measles cases from week-to-week. This marks 2 weeks in a row with a nearly identical increase of cases by percentage, and there are now 5 outbreaks circulating throughout the US.
IDSA’s Amanda Jezek provides the latest update on the legislative bill, including some of its features, its methodology for assigning antimicrobials to the subscription model, and how anyone can advocate for the bill with Congress.
Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID) describes the potential consequences, including morbidity and mortality rates, if the federal government removed these vaccines.
The Centers for Disease Control and Prevention (CDC) characterizes epidemiology, serotype and treatment resistance of extraintestinal invasive Escherichia coli, the most common pathogen in community-onset sepsis.
New amicus brief from scholars and professional organizations including the American Thoracic Society and American Academy of Allergy, Asthma & Immunology supports AAP lawsuit against HHS changes to pediatric vaccine schedule.
The FDA declined to review Moderna’s mRNA flu vaccine application for its mRNA-1010 product, and based its decision on it choice of comparator in a phase 3 trial, despite the absence of safety or efficacy concerns and prior FDA agreement on the study design. Moderna requested a meeting to understand the path forward with the vaccine.
A large international study published in The Lancet shows that obesity substantially increases the risk of severe illness and death from most infectious diseases, potentially accounting for more than 10% of infection-related deaths worldwide.
In a new policy paper, the American College of Physicians (ACP) argues that referring to physicians as “providers” is not merely semantic but contributes to the commercialization of medicine, eroding professional identity, ethical practice, and the physician–patient relationship.
Risk of a cardiac event was higher in older patients hospitalized for respiratory syncytial virus (RSV) infection than has been reported for influenza.
This week, listen in on commentary around the ongoing measles outbreak, read our new Antibiotics Deconstructed column on IV fosfomycin, review data on metformin preventing long COVID, insights on diagnostic stewardship, and more.
Alftan Dyson, PharmD, AAHIVP, FNPhA, discusses the significance of Black HIV/AIDS Awareness day as well as the importance of taking the discussion around HIV prevention and sexual health out into the communities to have those conversations.
The latest CDC numbers show a significant increase week-to-week.
In a phase 3 trial, the novel oral antiviral pritelivir demonstrated superior lesion healing and better tolerability than existing therapies in immunocompromised patients with refractory or resistant herpes simplex virus infections.
The FDA recently approved intravenous fosfomycin (Contepo), which is a new option for adults with complicated urinary tract infections, including those caused by resistant Gram-negative pathogens. Here is an overview of the therapeutic including its mechanism of action, data, availability, and prospective costs.
This is the fourth time the antimicrobial bill looking at a subscription-payment model has been introduced in the Congress and has some updates in how these therapeutics are developed and paid for with help from the federal government.
